Cynvenio, Milenia Labs Release: Companies Enter Into Exclusive Distribution Agreement For ClearID Breast Cancer Testing In Mexico

New Commercial Agreement brings Affordable and Comprehensive Liquid Biopsy Tests to Mexico

WESTLAKE VILLAGE, Calif. & ZACATECAS, Mexico--(BUSINESS WIRE)--Cynvenio Biosystems, Inc., a leader in individualized cancer diagnostics, and Milenia Labs, a provider of high-quality clinical and pathological diagnostic tests in Mexico, today announced a distribution agreement for Cynvenio’s ClearID^® Breast Cancer, the first blood test for treatment selection and monitoring of patients with advanced breast cancer. The agreement will make ClearID Breast Cancer exclusively available to customers through Milenia Labs and its network of 12 diagnostic centers in Mexico.

“We are excited to extend the reach of our tests and to help more patients receive advanced genomic testing and molecular monitoring in Mexico”

ClearID Breast Cancer is designed for patients undergoing treatment for advanced breast cancer and those who require follow-up testing at regular intervals after completion of therapy.

The test uses molecular analysis to rapidly and precisely generate real-time information on cancer cell activity. Using a normal blood draw, ClearID detects the presence of scarce populations of cancer cells in the bloodstream and identifies gene alterations known to signal resistance to therapy. Milenia will also offer Cynvenio’s PD-L1 gene expression reflex assay and other Cynvenio assays as they become commercially available.

“Liquid biopsy is revolutionizing the treatment of cancer in Mexico because it offers a better understanding of the genetic basis of cancer and is a non-invasive, personalized medicine tool that is very convenient and practical for the patient,” said Dr. Salvador Cardona, Milenia Labs’ Director General. “Our mission is to provide the Mexican market with the highest quality and most innovative diagnostic tests from international providers. Cynvenio’s ClearID Breast Cancer test provides an excellent new option for patients based on state of the art liquid biopsy technology that has the benefit of being more affordable compared to other tests in this category.”

Based on Cynvenio’s patented LiquidBiopsy^® approach to tumor monitoring, the ClearID test analyzes a combination of DNA from circulating tumor cells (CTC), cell-free DNA (cfDNA), and germline DNA (gDNA). This multi-sourced DNA analysis produces direct insights into the progression of the primary tumor and the metastatic disease process, while increasing specificity by using germline DNA as a built-in control to eliminate biological and instrument noise.

“We are excited to extend the reach of our tests and to help more patients receive advanced genomic testing and molecular monitoring in Mexico,” commented Humberto Huerta, Cynvenio’s Chief Commercial Officer, Clinical Diagnostics. “Milenia Labs has a successful track record of innovation in Mexico and an enviable network of partner labs throughout the country. This agreement is the cornerstone of our plan to broaden access to ClearID Breast testing services outside the United States.”

About Cynvenio Biosystems, Inc.

Cynvenio Biosystems, Inc. is a leader in the development of more affordable and clinically actionable precision medicine strategies for cancer patients. Cynvenio’s liquid biopsy tests accurately target known DNA & RNA mutations in cancer-related genes to revolutionize personalized treatment decision-making and clinical trial selection. Among the company’s breakthroughs are an expanding line of ClearID^® tests engineered for greatly improved cancer detection and monitoring via a patient-friendly blood draw, and proprietary LiquidBiopsy^® automated platform technology, which is distributable and makes real-time molecular tumor characterization from whole blood a practical reality for any lab. Cynvenio is based in Westlake Village, California. For more information, please visit www.cynvenio.com

About Milenia Labs

Milenia Labs, comprised of 12 centers across Mexico, works with international companies to offer specialized diagnostic tests to the Mexican market. The company’s goal is to provide the highest quality and most advanced and innovative technologies for clinical and pathological diagnostic tests through its partnerships with the best laboratories in the United States, Canada, and Europe. Milenia offers tests for a range of conditions, including non-invasive prenatal tests, cardio-metabolic panels, personalized genetic testing, and specialized oncology panels. For more information, please visit www.milenialabs.com